Duloxetine: clinical pharmacokinetics and drug interactions (Q37848815)

24 August 2017

1 reference

title

Duloxetine: clinical pharmacokinetics and drug interactions (English)

1 reference

24 August 2017

1 reference

Mary Pat Knadler

1

1 reference

24 August 2017

Evelyn Lobo

series ordinal

2

1 reference

24 August 2017

Jill Chappell

series ordinal

3

1 reference

24 August 2017

Richard Bergstrom

series ordinal

4

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 May 2011

1 reference

Clinical Pharmacokinetics

24 August 2017

published in

1 reference

24 August 2017

volume

50

1 reference

24 August 2017

issue

5

1 reference

24 August 2017

page(s)

281-294

1 reference

Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

LY248686, a new inhibitor of serotonin and norepinephrine uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

A retrospective pooled analysis of duloxetine safety in 23,983 subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

Duloxetine vs. placebo in patients with painful diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

Duloxetine for management of stress urinary incontinence

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

Safety and adverse event profile of duloxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

Population pharmacokinetics of orally administered duloxetine in patients: implications for dosing recommendation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

Duloxetine pharmacokinetics are similar in Japanese and Caucasian subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

Pharmacokinetics of duloxetine in breast milk and plasma of healthy postpartum women

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

Changes in plasma protein binding have little clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

Plasma protein binding displacement interactions--why are they still regarded as clinically important?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

A dose-finding study of duloxetine based on serotonin transporter occupancy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

Synthesis and biological activity of some known and putative duloxetine metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

A distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy Caucasian volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

The influence of smoking on the serum level of duloxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

Effect of age on the pharmacokinetics of duloxetine in women

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

Pharmacokinetics and tolerability of duloxetine following oral administration to healthy Chinese subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

Effects of varying degrees of renal impairment on the pharmacokinetics of duloxetine: analysis of a single-dose phase I study and pooled steady-state data from phase II/III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

The Conduct of In Vitro and In Vivo Drug-Drug Interaction Studies: A PhRMA Perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

Effect of duloxetine on tolterodine pharmacokinetics in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

The dosing of atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

Duloxetine for major depressive episodes in the course of psychotic disorders: an observational clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

Potential drug-drug interaction between duloxetine and acenocoumarol in a patient with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

Effects of duloxetine on the pharmacodynamics and pharmacokinetics of warfarin at steady state in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

Duloxetine serum concentrations and clinical effects. Data from a therapeutic drug monitoring (TDM) survey

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539240-000000000-00000

The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rate

21 January 2018

1 reference

12 December 2020

Duloxetine for the treatment of major depressive disorder in older patients

1 reference

12 December 2020

Duloxetine for the treatment of major depressive disorder.

1 reference

12 December 2020

Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities

1 reference

12 December 2020

An open-label study of duloxetine hydrochloride, a mixed serotonin and noradrenaline reuptake inhibitor, in patients with DSM-III-R major depressive disorder. Lilly Duloxetine Depression Study Group.

1 reference

12 December 2020

Duloxetine pharmacokinetics in cirrhotics compared with healthy subjects

1 reference

12 December 2020

Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine

1 reference

12 December 2020

An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies

1 reference

12 December 2020

Determination of duloxetine in human plasma via LC/MS and subsequent application to a pharmacokinetic study in healthy Chinese volunteers

1 reference

12 December 2020

Immediate switching from moclobemide to duloxetine may induce serotonin syndrome

1 reference

12 December 2020

Interaction of duloxetine and warfarin causing severe elevation of international normalized ratio

1 reference

12 December 2020

Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial

1 reference

12 December 2020

Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms.

1 reference

12 December 2020

10.2165/11539240-000000000-00000

Identifiers

DOI

1 reference

24 August 2017

1 reference